They are associated with drug resistance, including ANXA2 in nasopharyngeal carcinoma [20], ANXA3 in colorectal [21] and ovarian cancers [22], and ANXA5 in lung cancer [23]. This evidence concerns the gene ANXA3 and ovarian carcinoma.